Microplasmin looks promising for the treatment of vitreomacular traction

Article

ThromboGenics, a biotechnology company focused on vascular diseases, has completed patient enrolment for a Phase IIa trial designed to evaluate the safety and efficacy of microplasmin for the treatment of vitreomacular traction, including macular holes.

ThromboGenics, a biotechnology company focused on vascular diseases, has completed patient enrolment for a Phase IIa trial designed to evaluate the safety and efficacy of microplasmin for the treatment of vitreomacular traction, including macular holes.

The MIVI IIT trial is a Phase IIa, sham injection controlled, dose ascending (75, 125 µg) trial, which has recruited 30 patients in Europe. While the study remains masked, preliminary data demonstrates that microplasmin was well tolerated in both treatment groups and furthermore, posterior vitreous detachment (PVD) was seen in a number of patients and in some cases led to the non-surgical resolution of traction.

Unmasked results of the study will be presented later this year at the American Society of Retina Specialists annual meeting in California, US.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.